EP2274042A4 - Treatment and/or prevention of multiple sclerosis - Google Patents

Treatment and/or prevention of multiple sclerosis

Info

Publication number
EP2274042A4
EP2274042A4 EP09730371A EP09730371A EP2274042A4 EP 2274042 A4 EP2274042 A4 EP 2274042A4 EP 09730371 A EP09730371 A EP 09730371A EP 09730371 A EP09730371 A EP 09730371A EP 2274042 A4 EP2274042 A4 EP 2274042A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
multiple sclerosis
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09730371A
Other languages
German (de)
French (fr)
Other versions
EP2274042A1 (en
Inventor
Brian Murphy
Michael Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epiphany Biosciences Inc
Original Assignee
Epiphany Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epiphany Biosciences Inc filed Critical Epiphany Biosciences Inc
Publication of EP2274042A1 publication Critical patent/EP2274042A1/en
Publication of EP2274042A4 publication Critical patent/EP2274042A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09730371A 2008-04-11 2009-04-10 Treatment and/or prevention of multiple sclerosis Withdrawn EP2274042A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12378708P 2008-04-11 2008-04-11
US19252908P 2008-09-18 2008-09-18
US20904509P 2009-03-03 2009-03-03
PCT/US2009/002276 WO2009126327A1 (en) 2008-04-11 2009-04-10 Treatment and/or prevention of multiple sclerosis

Publications (2)

Publication Number Publication Date
EP2274042A1 EP2274042A1 (en) 2011-01-19
EP2274042A4 true EP2274042A4 (en) 2012-03-14

Family

ID=41162179

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09730371A Withdrawn EP2274042A4 (en) 2008-04-11 2009-04-10 Treatment and/or prevention of multiple sclerosis

Country Status (3)

Country Link
EP (1) EP2274042A4 (en)
CA (1) CA2721148A1 (en)
WO (1) WO2009126327A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201819197A2 (en) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012313A1 (en) * 1993-11-05 1995-05-11 Pathogenesis Corporation Virus associated multiple sclerosis: treatments, prevention and diagnosis thereof
WO1996027378A2 (en) * 1995-03-07 1996-09-12 Smithkline Beecham Plc Use of penciclovir for the treatment of human herpes-virus-8
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012313A1 (en) * 1993-11-05 1995-05-11 Pathogenesis Corporation Virus associated multiple sclerosis: treatments, prevention and diagnosis thereof
WO1996027378A2 (en) * 1995-03-07 1996-09-12 Smithkline Beecham Plc Use of penciclovir for the treatment of human herpes-virus-8
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009126327A1 *

Also Published As

Publication number Publication date
CA2721148A1 (en) 2009-10-15
EP2274042A1 (en) 2011-01-19
WO2009126327A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
HRP20190059T1 (en) Compositions for the treatment of pain and/or inflammation
HK1207594A1 (en) Compositions and methods for the prevention and treatment of autoimmune conditions
ZA200904806B (en) Prevention and treatment of sub-clinical pcvd
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
PL2118074T3 (en) Compounds for the prevention and treatment of cardiovascular diseases
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
IL202126A0 (en) Treatment and prevention of influenza
EP2651439A4 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PL2254589T3 (en) Compounds and methods for the prevention or treatment of restenosis
HK1167101A1 (en) Compositions and methods for treatment of multiple sclerosis
HK1130434A1 (en) Treatment and prevention of excessive scarring
EP2274042A4 (en) Treatment and/or prevention of multiple sclerosis
HK1185345A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
AP3019A (en) Use of ferroquine in the treatment or prevention of malaria
HU0800012D0 (en) Novel use and methods for the treatment and prevention of ulcerative colitis
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0808730D0 (en) Compositions and methods for the prevention and treatment of schistosomiasis
EP2276502A4 (en) Compositions for the prevention and treatment of neuroinjury and methods of use thereof
GB0724970D0 (en) Treatment and prevention of nuerodegenerative diseases
GB0612749D0 (en) Treatment and/or prevention of pain
TWI367093B (en) Hydroxy-morusin-treatment and/or prevention of mouth diseases
IL219212A0 (en) Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
GB201020304D0 (en) Treatment and prevention of pain
GB0811950D0 (en) Disease prevention and treatment
EP1998791A4 (en) Suppression and treatment of neuropathic pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120213

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALN20120207BHEP

Ipc: A61P 31/22 20060101ALN20120207BHEP

Ipc: A61M 37/00 20060101AFI20120207BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120912